Novavax Inc. (NVAX) Technical analysis
Healthcare
Market data as of 2026-09-04 · Autonium metric computed 2026-09-04 · model v1NVAX technical analysis — the short answer
NVAX is classified Uptrend with a 14-day RSI of 70.7, three-month return of +7.7% and 20-day realised volatility of 58.8%. Autonium's composite Algo Score currently reads 85/100.
Price versus moving averages
Last close10.22
20-day8.92+14.6%
50-day8.58+19.2%
100-day8.84+15.7%
200-day8.55+19.5%
Trend classificationUptrend
Returns
1 week+10.4%
1 month+32.0%
3 months+7.7%
6 months+2.4%
12 months+31.2%
Volatility and drawdown
Realised volatility (20d, annualised)+58.8%
Realised volatility (60d, annualised)+50.0%
1-year volatility percentile56
Current drawdown from peak-8.7%
Deepest 1-year drawdown-34.9%
SPY volatility (20d)+8.1%
Autonium Algo Score
Current score85 / 100
7-day change-3
30-day change+61
90-day change+79
1-year range1 – 93
Readings above 7016
Readings below 3033
Signal drivers
MomentumPositive
Technical trendPositive
VolatilityNeutral
SentimentNeutral
NVAX's Algo Score fell 3 points over the last seven days. The factors currently reading positive are momentum, technical trend; reading negative: none.
Sector peers — 3-month return
LLY — Eli Lilly and Co.1.6
UNH — UnitedHealth Group-0.6
JNJ — Johnson & Johnson18.2
ABBV — AbbVie Inc.12.9
MRK — Merck & Co.24.5
Bullish signals
- Price above the 50-day average
- Price above the 200-day average
- +3.3% three-month excess return vs SPY
Neutral signals
- Volatility in the 56th percentile of its own year
- Normal volume regime
Bearish signals
- RSI stretched at 70.7
Score history
- 2026-09-0785
- 2026-09-0485
- 2026-09-0385
- 2026-09-0286
- 2026-09-0193
- 2026-08-3188
- 2026-08-2881
- 2026-08-2779
- 2026-08-2679
- 2026-08-2581
- 2026-08-2469
- 2026-08-2180
Track NVAX inside Autonium
Full factor detail, alerts when the score changes, and Toni to ask why.
Continue analysing NVAX
Autonium publishes research, not recommendations. Scores, factors and written reads describe historical and current data and are not buy or sell advice. Not financial advice. Market data is refreshed on a schedule and may lag. See our methodology and disclosures.